ウェアラブルインジェクター - 世界市場の考察、競合情勢、市場予測（2030年）

世界のウェアラブルインジェクターの市場規模は、2023年に67億2,558万米ドル、2030年までに138億1,556万米ドルに達し、2024年～2030年の予測期間にCAGRで12.78％の成長が見込まれます。市場は主に、がん、糖尿病、心血管障害などの慢性疾患の増加により、楽観的な成長を示しています。さらに、針刺しに関する危険性や制限に対する懸念の高まりや、治療に対する患者コンプライアンスへのニーズや需要の高まり、デバイスにおける技術革新や技術の進歩は、市場におけるウェアラブルインジェクターへのニーズを生み出す見込みです。さらに、製品の発売や承認の増加や、世界中での償還シナリオの向上が、ウェアラブルインジェクター市場の全体的な成長をさらに加速させます。したがって、ウェアラブルインジェクター市場は2024年～2030年の予測期間に大幅なCAGRでの成長が見込まれます。

ウェアラブルインジェクターの市場力学

世界保健機関（WHO）（2022）のファクトシートによると、がんは世界の主な死因であり、2020年に約1,000万人が死亡しています。2020年における乳がんの新規患者数は226万人、次いで肺がん221万人、大腸がん193万人、前立腺がん141万人、皮膚がん120万人、胃がん109万人となっています。

International Diabetes Federation（2022）第10版によると、5億3,700万人近くの成人（20～79歳）が糖尿病を患っています。この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。

このように、慢性疾患の有病率の増加は、ウェアラブルインジェクターの需要の増加につながります。心血管疾患は、世界的に主要な死因であると考えられています。2023年の世界保健機関（WHO）によると、2019年に推定1,790万人が心血管障害で死亡し、全世界の死亡者数の32％を占める。2019年の非伝染性疾患による1,700万人の早死（70歳未満）のうち、38％が心血管障害によるものでした。ウェアラブルインジェクターを適切なタイミングで使用して心血管患者に薬剤を投与すれば、死亡率を低下させたり抑制したりすることができます。したがって、ウェアラブルインジェクターの需要の増加につながり、ひいては市場全体の成長を後押しします。

主要市場企業によって採用された革新的な製品を発売するためのさまざまな戦略が、さらに予測期間に市場の成長を支援すると予測されています。例えば、2022年2月、Molexの子会社でドラッグデリバリー、診断、メドテックデバイスの設計、開発、製造のリーダーであるPhillips-Medisizeは、独自のデバイスプラットフォームの世界的イノベーターであるSubcujectと協業し、画期的なウェアラブルボーラスインジェクターを市場に投入しました。

したがって、上記の要因が2024年～2030年の予測期間にウェアラブルインジェクター市場全体を牽引します。

しかし、代替のドラッグデリバリー方式への選好や、システムのナノ粒子に起因する一定の副作用、ウェアラブルインジェクターの高いコストなどが、世界のウェアラブルインジェクター市場の成長を抑制する可能性があります。

COVID-19パンデミックはウェアラブルインジェクター市場に大きな影響を与えています。パンデミックの発生は、厳格なソーシャルディスタンス規範や、人々の交流の減少、消費者の移動の制限につながり、消費者はウェアラブルインジェクターを購入するために店舗を訪れることが困難になり、ウェアラブルインジェクターの使用率が低下し、それによってロックダウンの初期にウェアラブルインジェクターの需要と市場全体を減退させました。しかし、パンデミック中、薬の自己投与に用いるウェアラブルインジェクターの需要が高まり、ウェアラブルインジェクターの需要が増加しました。さらに、サプライチェーン、製造、ロックダウンの制限の緩和、ウェアラブルインジェクターのeコマース販売の増加傾向に伴い、ウェアラブルインジェクターの市場は健全な成長率で拡大しました。このように、上記の要因により、ウェアラブルインジェクタービジネスはパンデミックの残り半分で大きな成長を遂げ、今後数年間で同様に傾向が上昇すると予想されます。

当レポートでは、世界のウェアラブルインジェクター市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 ウェアラブルインジェクター市場レポートのイントロダクション

第2章 ウェアラブルインジェクター市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 ウェアラブルインジェクター市場の主な要因の分析

• ウェアラブルインジェクター市場の促進要因
  • がん、糖尿病、心血管障害を中心とした慢性疾患の罹患率の増加
  • 針刺しに関連する危険性と制限に対する懸念の高まり
  • 治療についての患者コンプライアンスに対するニーズと需要の高まり
  • デバイスのイノベーションと技術の進歩
• ウェアラブルインジェクター市場の抑制要因と課題
  • 代替のドラッグデリバリー方式への選好
  • システムのナノ粒子によって引き起こされる一定の副作用
  • ウェアラブルインジェクターの高いコスト
• ウェアラブルインジェクター市場の機会
  • 高齢者の意識の高まりにより、スマート/デジタルウェアラブルインジェクターの需要も高まっている
  • 世界中でのさまざまな医薬品の開発とバイオ医薬品の急速な成長

第5章 ウェアラブルインジェクター市場のポーターのファイブフォース分析

第6章 ウェアラブルインジェクター市場に対するCOVID-19の影響分析

第7章 ウェアラブルインジェクター市場レイアウト

• タイプ別
  • オンボディインジェクター
  • オフボディインジェクター
• 適応症別
  • 腫瘍
  • 自己免疫疾患
  • 糖尿病
  • 循環器疾患
  • その他
• エンドユーザー別
  • 病院、診療所
  • 在宅ケア
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 ウェアラブルインジェクター市場の企業と製品のプロファイル

• BD
• Ypsomed
• Amgen Inc.
• West Pharmaceutical Services, Inc.
• Stevanato Group
• Eitan Medical
• United Therapeutic Corporation
• Buhler Motor GmbH
• Sonceboz
• Subcuject Aps
• Nemera
• SHL Medical AG
• Gerresheimer AG
• Insulet Corporation
• CeQur SA

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Wearable Injectors Market Analysis in Global (2021-2030)
• Table 4: Wearable Injectors Market Analysis in Global by Type (2021-2030)
• Table 5: Wearable Injectors Market Analysis in Global by Indication (2021-2030)
• Table 6: Wearable Injectors Market Analysis in Global by End-User (2021-2030)
• Table 7: Wearable Injectors Market Analysis in Global by Geography (2021-2030)
• Table 8: Wearable Injectors Market Analysis in North America (2021-2030)
• Table 9: Wearable Injectors Market Analysis in North America by Country (2021-2030)
• Table 10: Wearable Injectors Market Analysis in the US (2021-2030)
• Table 11: Wearable Injectors Market Analysis in Canada (2021-2030)
• Table 12: Wearable Injectors Market Analysis in Mexico (2021-2030)
• Table 13: Wearable Injectors Market Analysis in Europe (2021-2030)
• Table 14: Wearable Injectors Market Analysis in Europe by Country (2021-2030)
• Table 15: Wearable Injectors Market Analysis in France (2021-2030)
• Table 16: Wearable Injectors Market Analysis in Germany (2021-2030)
• Table 17: Wearable Injectors Market Analysis in the United Kingdom (2021-2030)
• Table 18: Wearable Injectors Market Analysis in Italy (2021-2030)
• Table 19: Wearable Injectors Market Analysis in Spain (2021-2030)
• Table 20: Wearable Injectors Market Analysis in Russia (2021-2030)
• Table 21: Wearable Injectors Market Analysis in the Rest of Europe (2021-2030)
• Table 22: Wearable Injectors Market Analysis in APAC (2021-2030)
• Table 23: Wearable Injectors Market Analysis in APAC by Country (2021-2030)
• Table 24: Wearable Injectors Market Analysis in China (2021-2030)
• Table 25: Wearable Injectors Market Analysis in Japan (2021-2030)
• Table 26: Wearable Injectors Market Analysis in India (2021-2030)
• Table 27: Wearable Injectors Market Analysis in Australia (2021-2030)
• Table 28: Wearable Injectors Market Analysis in South Korea (2021-2030)
• Table 29: Wearable Injectors Market Analysis in Rest of APAC (2021-2030)
• Table 30: Wearable Injectors Market Analysis in the Rest of the World (2021-2030)
• Table 31: Wearable Injectors Market Analysis in RoW by Region (2021-2030)
• Table 32: Wearable Injectors Market Analysis in the Middle East (2021-2030)
• Table 33: Wearable Injectors Market Analysis in Africa (2021-2030)
• Table 34: Wearable Injectors Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Wearable Injectors Market Analysis in Global (2021-2030)
• Figure 4: Wearable Injectors Market Analysis in Global by Type (2021-2030)
• Figure 5: Wearable Injectors Market Analysis in Global by Indication (2021-2030)
• Figure 6: Wearable Injectors Market Analysis in Global by End-User (2021-2030)
• Figure 7: Wearable Injectors Market Analysis in Global by Geography (2021-2030)
• Figure 8: Wearable Injectors Market Analysis in North America (2021-2030)
• Figure 9: Wearable Injectors Market Analysis in North America by Country (2021-2030)
• Figure 10: Wearable Injectors Market Analysis in the US (2021-2030)
• Figure 11: Wearable Injectors Market Analysis in Canada (2021-2030)
• Figure 12: Wearable Injectors Market Analysis in Mexico (2021-2030)
• Figure 13: Wearable Injectors Market Analysis in Europe (2021-2030)
• Figure 14: Wearable Injectors Market Analysis in Europe by Country (2021-2030)
• Figure 15: Wearable Injectors Market Analysis in France (2021-2030)
• Figure 16: Wearable Injectors Market Analysis in Germany (2021-2030)
• Figure 17: Wearable Injectors Market Analysis in the United Kingdom (2021-2030)
• Figure 18: Wearable Injectors Market Analysis in Italy (2021-2030)
• Figure 19: Wearable Injectors Market Analysis in Spain (2021-2030)
• Figure 20: Wearable Injectors Market Analysis in Russia (2021-2030)
• Figure 21: Wearable Injectors Market Analysis in the Rest of Europe (2021-2030)
• Figure 22: Wearable Injectors Market Analysis in APAC (2021-2030)
• Figure 23: Wearable Injectors Market Analysis in APAC by Country (2021-2030)
• Figure 24: Wearable Injectors Market Analysis in China (2021-2030)
• Figure 25: Wearable Injectors Market Analysis in Japan (2021-2030)
• Figure 26: Wearable Injectors Market Analysis in India (2021-2030)
• Figure 27: Wearable Injectors Market Analysis in Australia (2021-2030)
• Figure 28: Wearable Injectors Market Analysis in South Korea (2021-2030)
• Figure 29: Wearable Injectors Market Analysis in Rest of APAC (2021-2030)
• Figure 30: Wearable Injectors Market Analysis in the Rest of the World (2021-2030)
• Figure 31: Wearable Injectors Market Analysis in RoW by Region (2021-2030)
• Figure 32: Wearable Injectors Market Analysis in the Middle East (2021-2030)
• Figure 33: Wearable Injectors Market Analysis in Africa (2021-2030)
• Figure 34: Wearable Injectors Market Analysis in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Wearable Injectors Market By Type (On-Body Injectors And Off-Body Injectors), By Indication (Oncology, Autoimmune Disease, Diabetes, Cardiovascular Disease, And Others), By End-User (Hospitals & Clinics, Home Care, And Others), and by geography expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of various chronic diseases such as cancers, diabetes, cardiovascular, among others and the rising innovations and technological advancement in this arena

The global wearable injectors market was valued at USD 6,725.58 million in 2023, growing at a CAGR of 12.78% during the forecast period from 2024 to 2030 to reach USD 13,815.56 million by 2030. The wearable injectors market is indorsing optimistic growth primarily owing to the increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others. Further, rising concern over the hazards and limitations related to needle sticks, rising need & demand for patient compliance to treatment, and rising innovations & technological advancement in the device will create a requisite for wearable injectors in the market. In addition, the increasing product launches and approvals, and the rising reimbursement scenarios across the globe will further upsurge the overall growth of the wearable injectors market. Therefore, the market for wearable injectors is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.

Wearable Injectors Market Dynamics:

According to World Health Organization (WHO) 2022 factsheet, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The new cases of breast cancer in 2020 was 2.26 million, followed by lung cancer with 2.21 million cases, colon and rectum cancer reported 1.93 million news cases, prostate cancer 1.41 million cases, skin cancer - 1.20 million cases and stomach cancer 1.09 million cases, worldwide.

As per the 10th Edition of the International Diabetes Federation 2022, nearly 537 million adults (20-79 years) were living with diabetes. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Thus, the increasing prevalence of chronic diseases will, leads to an increase in demand for wearable injectors as the injectors are used for administering various drugs over an extended period to patients suffering from chronic diseases. Cardiovascular diseases are considered to be the leading cause of death globally. As per the World Health Organization in the year 2023, an estimated 17.9 million people died from cardiovascular disorders in 2019, illustrating 32% of all global deaths. Out of the 17 million premature deaths (under the age of 70 years) due to non-communicable diseases in 2019, 38% of the deaths were caused due to cardiovascular disorders. The mortality rate can be reduced or controlled if the wearable injectors are used at an apt time to administer the drugs to the cardiovascular patients. Thus, leading to an increased demand of wearable injectors, ultimately propelling the overall market growth.

The various strategies adopted by key market players to launch innovative products are further expected to aid the market's growth over the forecast period. For example, in February 2022, Phillips-Medisize, a Molex company and a leader in the design, development, and manufacturing of drug delivery, diagnostic, and MedTech devices, collaborated with Subcuject, a global innovator of proprietary device platforms, to bring to market a game-changing wearable bolus injector.

Therefore, the factors stated above collectively will drive the overall market of wearable injectors during the forecast period from 2024-2030.

However, the preference for alternative drug delivery modes, certain side effects caused due to the nanoparticles of the system, and the high cost of the wearable injectors, among others, can hinder the global wearable injector's market growth.

The COVID-19 pandemic has significantly impacted the market for wearable injectors. The outbreak of the pandemic led to strict social distancing norms, reduced socializing among people, and restrictions on mobility among consumers directed to a drop in wearable injectors usage with consumers finding it hard to visit stores to buy the wearable injectors, thereby decreasing the demand and overall market of wearable injectors in the initial phase of the lockdown. However, the rising demand for wearable injectors for the self-administration of drugs during to pandemic led to an increased demand for wearable injectors. Moreover, with the ease in the supply chain, manufacturing, & lockdown restrictions, and the increasing trend of e-commerce sales for wearable injectors the market of wearable injectors increased at a healthy growth rate. Thus, owing to the above-mentioned factors the wearable injectors business registered a lucrative growth in the other half of the pandemic, and the trend is anticipated to rise in the same manner in the upcoming years.

Wearable Injectors Market Segment Analysis:

Wearable Injectors Market by Type (On-Body Injectors and Off-Body Injectors), Indication (Oncology, Autoimmune Disease, Diabetes, Cardiovascular Disease, and Others), End-User (Hospitals & Clinics, Home Care, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy segment of the wearable injectors market, the oncology segment tends to hold a significant revenue share in the year 2023. This was primarily owing to the rising incidences of various cancers across the globe.

For instance, according to a 2022 update by the World Health Organization (WHO), the new cancer cases in 2020 were breast cancer with 2.26 million cases, lung cancer is the second most common cancer type with 2.21 million cases followed by colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, skin (non-melanoma) cancer with 1.20 million cases, and stomach cancer with 1.09 million cases.

The latest data published by the Canadian Cancer Society estimates that approximately 7% of Canadian males will get lung and bronchus cancer in their lifetime, and approximately 5% will pass away from it, every year.

Further, there are several biologic drugs for oncology, but they necessitate frequent administration and visits to a hospital or specialized clinic, resulting in high costs and patient discomfort. Wearable injectors are gaining popularity among oncology patients because they allow patients to self-administer the drug, improving their lives. Essentially, their ability to deliver anti-tumor agents automatically and safely is a key growth driver for this category.

Recent strategic activities such as product launches in the domain of wearable injectors will also drive market growth. For instance, in August 2022, BD results from a 52-subject human clinical trial with the BD Libertas Wearable Injector were announced. The subcutaneous drug delivery system, currently in the final phases of development, is designed to be ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

Thus, the aforesaid factors will in turn drive the oncology segment market in the wearable injectors market, thereby propelling the overall market growth of wearable injectors during the forecast period from 2022 - 2028.

North America is expected to dominate the overall Wearable Injectors Market:

Among all the regions, North America is expected to dominate the global wearable injectors market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This domination is attributed to the rising prevalence of chronic diseases & lifestyle-related diseases, the presence of sophisticated healthcare infrastructure, presence of key players in the region, among others are the key factors contributing to the wearable injectors market growth in the country and is expected to aid in the growth of the North America wearable injectors devices market.

For instance, as per the data provided by the American Cancer Society, it is estimated that in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. This indicates that the incidence and mortality rate associated with cancer are significantly high, which increases the demand for surgical procedures, subsequently boosting the demand for drug delivery devices such as wearable injectors driving the market growth.

Also, according to the American Diabetes Association data published in February 2022, diabetes affects more than 29 million people in North America, with that number expected to rise to 33 million by 2026. The large prevalence of these diseases is expected to drive the growth in demand for wearable injectors in the region.

Furthermore, various strategic initiatives taken by the market players, such as product launches, collaborations, mergers, and acquisitions, are expected to boost the market in North America. For instance, in April 2022, CeQur, a maker of insulin delivery devices based in Marlborough, raised USD 115 million in funding as it launched its wearable insulin injector, CeQur Simplicity.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the North America region in the wearable injectors market.

Wearable Injectors Market Key Players:

Some of the key market players operating in the wearable injectors market include BD, Ypsomed, Amgen Inc., West Pharmaceutical Services, Inc., Stevanato Group, Eitan Medical, United Therapeutic Corporation, Buhler Motor GmbH, Sonceboz, Subcuject Aps, Nemera, SHL Medical AG, Gerresheimer AG, Insulet Corporation, CeQur SA, and others.

Recent Developmental Activities in the Wearable Injectors Market:

In June 2022, AbbVie received United States Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD). It can be self-administered by subcutaneous injection (SC) with an on-body injector (OBI).

In February 2022, Enable Injections raised a USD 215 million round to fund work on the subcutaneous drug delivery system enFuse. The device consists of a wearable delivery disc and a system for transferring the drug from its original vessel.

In February 2020, BD announced that it has completed the human clinical trial of its BD Libertas Wearable Injector with 50 subjects.

Key Takeaways from the Wearable Injectors Market Report Study

Market size analysis for the current wearable injectors market (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the wearable injectors market

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global wearable injectors market

Various opportunities are available for the other competitor in the wearable injectors market space

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current wearable injector's market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for wearable injector's market growth in the coming future?

Target Audience who can be benefited from this Wearable Injectors Report Study

Wearable Injectors market providers

Research organizations and consulting companies

Wearable Injectors market-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and traders dealing in the wearable injectors market

Various end-users who want to know more about the wearable injectors market and the latest developments in the wearable injectors market

Frequently Asked Questions for the Wearable Injectors Market:

1. What are wearable injectors?

Wearable injectors are delivery systems that adhere to the body to administer larger volumes (more than 2 mL) of drug subcutaneously over an extended period.

2. What is the market for wearable injectors?

The global wearable injectors market was valued at USD 6,725.58 million in 2023, growing at a CAGR of 12.78% during the forecast period from 2024 to 2030 to reach USD 13,815.56 million by 2030.

3. What are the drivers for the wearable injectors market?

The wearable injectors market is witnessing positive market growth owing to the factors such as the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others, increasing concern over the hazards and limitations related to needlesticks, rising need and demand for patient compliance to treatment, rising innovations and technological advancement in the device, and the surging launches and approvals of different types of wearable injectors in the market.

4. Who are the key players operating in the wearable injectors market?

Some of the key market players operating in the wearable injectors market include BD, Ypsomed, Amgen Inc., West Pharmaceutical Services, Inc., Stevanato Group, Eitan Medical, United Therapeutic Corporation, Buhler Motor GmbH, Sonceboz, Subcuject Aps, Nemera, SHL Medical AG, Gerresheimer AG, Insulet Corporation, CeQur SA, and others.

5. Which region has the highest share in the wearable injectors market?

North America is expected to hold the largest share of the global wearable injectors market. Factors contributing to the growth are the rising prevalence of chronic diseases & lifestyle-related diseases, the presence of sophisticated healthcare infrastructure, the presence of key players in the region, and others that are contributing to the growth of wearable injectors in the North America region.

Table of Contents

1.Wearable Injectors Market Report Introduction

2. Wearable Injectors Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The US
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Wearable Injectors Market Key Factors Analysis

• 4.1. Wearable Injectors Market Drivers
  • 4.1.1. Increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others
  • 4.1.2. Increasing concern over the hazards and limitations related to needlestick
  • 4.1.3. Rising need and demand for patient compliance with treatment
  • 4.1.4. Rising innovations and technological advancement in the device
• 4.2. Wearable Injectors Market Restraints And Challenges
  • 4.2.1. Preference for alternative drug delivery modes
  • 4.2.2. Certain side effects caused due to the nanoparticles of the system
  • 4.2.3. High cost of the wearable injectors
• 4.3. Wearable Injectors Market Opportunities
  • 4.3.1. The increasing awareness among elderly people has also increased the demand for smart or digital wearable injectors
  • 4.3.2. The rapid growth of the biopharmaceuticals and development of various drugs across the globe

5. Wearable Injectors Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Wearable Injectors Market

7. Wearable Injectors Market Layout

• 7.1. By Type
  • 7.1.1. On-Body Injectors
  • 7.1.2. Off-Body Injectors
• 7.2. By Indication
  • 7.2.1. Oncology
  • 7.2.2. Autoimmune Disease
  • 7.2.3. Diabetes
  • 7.2.4. Cardiovascular Disease
  • 7.2.5. Others
• 7.3. By End-User
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Home care
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.1.2. Canada Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.1.3. Mexico Wearable Injectors Market Size in USD Million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.2.2. Germany Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.2.3. United Kingdom Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.2.4. Italy Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.2.5. Spain Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.2.6. Rest of Europe Wearable Injectors Market Size in USD Million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.3.2. Japan Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.3.3. India Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.3.4. Australia Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.3.5. South Korea Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Wearable Injectors Market Size in USD Million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.4.2. Africa Wearable Injectors Market Size in USD Million (2021-2030)
    • 7.4.4.3. South America Wearable Injectors Market Size in USD Million (2021-2030)

8. Wearable Injectors Market Company and Product Profiles

• 8.1. BD
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Ypsomed
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Amgen Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. West Pharmaceutical Services, Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Stevanato Group
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Eitan Medical
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. United Therapeutic Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Buhler Motor GmbH
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Sonceboz
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Subcuject Aps
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Nemera
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. SHL Medical AG
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Gerresheimer AG
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Insulet Corporation
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. CeQur SA
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us